CRL Charles River Laboratories International Inc

  1. Stocks
  2. Healthcare
  3. NYSE: CRL

Price (delayed)

$233.47

Market cap

$12.03B

P/E Ratio

27.31

Dividend/share

N/A

EPS

$8.55

Enterprise value

$14.78B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The equity is up by 17% year-on-year
The quick ratio is up by 17% since the previous quarter and by 16% year-on-year
The price to earnings (P/E) is 17% lower than the 5-year quarterly average of 31.4 but 3.3% higher than the last 4 quarters average of 25.1
The EPS fell by 12% YoY and by 8% QoQ
The net income has declined by 10% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.criver.com/
Peers: RGEN TMO SCYX

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
51.51M
Market cap
$12.03B
Enterprise value
$14.78B
Valuations
Price to earnings (P/E)
27.31
Price to book (P/B)
3.29
Price to sales (P/S)
2.92
EV/EBIT
21.73
EV/EBITDA
14.74
EV/Sales
3.59
Earnings
Revenue
$4.11B
EBIT
$680.14M
EBITDA
$1B
Free cash flow
$413.61M
Per share
EPS
$8.55
Free cash flow per share
$8.04
Book value per share
$70.89
Revenue per share
$79.93
TBVPS
$82.72
Balance sheet
Total assets
$8.15B
Total liabilities
$4.45B
Debt
$3.08B
Equity
$3.64B
Working capital
$713.38M
Liquidity
Debt to equity
0.85
Current ratio
1.75
Quick ratio
1.17
Net debt/EBITDA
2.74
Margins
EBITDA margin
24.4%
Gross margin
35.7%
Net margin
10.8%
Operating margin
14%
Efficiency
Return on assets
5.5%
Return on equity
12.7%
Return on invested capital
11.6%
Return on capital employed
9.4%
Return on sales
16.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
5.26%
1 week
6.98%
1 month
12.95%
1 year
9.59%
YTD
-1.24%
QTD
13.02%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.11B
Gross profit
$1.47B
Operating income
$575.35M
Net income
$444.45M
Gross margin
35.7%
Net margin
10.8%
The operating margin fell by 15% YoY and by 6% QoQ
CRL's operating income is down by 14% YoY and by 7% QoQ
Charles River Laboratories International's net margin has decreased by 11% YoY and by 6% QoQ
The net income has declined by 10% year-on-year and by 6% since the previous quarter

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
CRL P/E details
P/E
27.31
P/B
3.29
P/S
2.92
EV/EBIT
21.73
EV/EBITDA
14.74
EV/Sales
3.59
The price to earnings (P/E) is 17% lower than the 5-year quarterly average of 31.4 but 3.3% higher than the last 4 quarters average of 25.1
The EPS fell by 12% YoY and by 8% QoQ
The price to book (P/B) is 37% lower than the 5-year quarterly average of 5.0 and 8% lower than the last 4 quarters average of 3.4
The equity is up by 17% year-on-year
The P/S is 21% lower than the 5-year quarterly average of 3.5

Efficiency

How efficient is Charles River Laboratories International business performance
The ROE has contracted by 27% YoY and by 11% from the previous quarter
The company's return on assets fell by 17% YoY and by 10% QoQ
The company's return on invested capital fell by 8% YoY and by 6% QoQ
The ROS fell by 7% YoY and by 4.1% QoQ

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 83% higher than its total liabilities
Charles River Laboratories International's current ratio has increased by 18% YoY and by 15% from the previous quarter
The quick ratio is up by 17% since the previous quarter and by 16% year-on-year
Charles River Laboratories International's debt is 15% lower than its equity
Charles River Laboratories International's debt to equity has decreased by 17% YoY
The equity is up by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.